## FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden

| STATEMENT | <b>OF CHANGES</b> | IN BENEFICIAL | OWNERSHIP |
|-----------|-------------------|---------------|-----------|
|           |                   |               |           |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person <sup>*</sup><br>Townsend Adam J.                    |         |                | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br><u>Apellis Pharmaceuticals, Inc.</u> [ APLS ] | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>Director 10% Owner  |
|---|---------|----------------|---|---|
| (Last) (First) (Middle)<br>C/O APELLIS PHARMACEUTICALS, INC.<br>100 FIFTH AVENUE, 3RD FLOOR |         | EUTICALS, INC. | 3. Date of Earliest Transaction (Month/Day/Year)<br>10/03/2022                                      | X Officer (give title Other (specify below) below)<br>Chief Commercial Officer  |
| (Street)<br>WALTHAM   | MA      | 02451          | 4. If Amendment, Date of Original Filed (Month/Day/Year)  | 6. Individual or Joint/Group Filing (Check Applicable<br>Line)<br>X Form filed by One Reporting Person<br>Form filed by More than One Reporting<br>Person |
| (City)  | (State) | (Zip)          | rivative Securities Acquired. Disposed of. or Ben   | eficially Owned   |

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |                         |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and<br>5) |               |         | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported |   | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|-------------------------|---|---|---------------|---------|---|---|---|
|                                 |  |   | Code                    | v | Amount  | (A) or<br>(D) | Price   | Transaction(s)<br>(Instr. 3 and 4)  |   | (1130.4)  |
| Common Stock                    | 10/03/2022                                 |   | <b>M</b> <sup>(1)</sup> |   | 5,000   | A             | \$15.09 | 47,907  | D |   |
| Common Stock                    | 10/03/2022                                 |   | <b>S</b> <sup>(1)</sup> |   | 5,000   | D             | \$66.69 | 42,907  | D |   |

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| (.3),   |   |  |   |                              |   |     |       |  |                    |  |  |   |  |  |  |
|---|---|--|---|------------------------------|---|-----|-------|--|--------------------|--|--|---|--|--|--|
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of  |       | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|   |   |  |   | Code                         | v | (A) | (D)   | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Stock<br>Option<br>(Right to<br>Buy)                | \$15.09   | 10/03/2022                                 |   | <b>M</b> <sup>(1)</sup>      |   |     | 5,000 | (2)  | 11/15/2028         | Common<br>Stock  | 5,000                                  | \$0   | 317,500  | D  |  |

**Explanation of Responses:** 

1. This is a scheduled exercise and sale form an established 10b5-1 plan.

2. This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service

> /s/ David Watson, attorney-infact for Adam Townsend

10/05/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

hours per response:

0.5